Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Accured Expenses (2021 - 2025)

ARS Pharmaceuticals' Change in Accured Expenses history spans 5 years, with the latest figure at -$9.1 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 218.27% year-over-year to -$9.1 million; the TTM value through Dec 2025 reached $18.9 million, up 15.04%, while the annual FY2025 figure was $18.9 million, 15.04% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$9.1 million at ARS Pharmaceuticals, down from $11.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $12.8 million in Q2 2025 and bottomed at -$11.4 million in Q4 2022.
  • The 5-year median for Change in Accured Expenses is $1.2 million (2023), against an average of $1.2 million.
  • The largest annual shift saw Change in Accured Expenses surged 1268.75% in 2024 before it plummeted 218.27% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$5.4 million in 2021, then tumbled by 109.67% to -$11.4 million in 2022, then rose by 22.25% to -$8.9 million in 2023, then surged by 186.3% to $7.7 million in 2024, then tumbled by 218.27% to -$9.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Change in Accured Expenses are -$9.1 million (Q4 2025), $11.0 million (Q3 2025), and $12.8 million (Q2 2025).